Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Employees - 10,
CEO - Mr. Peter H. Nielsen MBA,
Sector - Healthcare,
Country - US,
Market Cap - 4.59M
Altman ZScore(max is 10): -67.23, Piotroski Score(max is 10): 2, Working Capital: $-476000, Total Assets: $2965000, Retained Earnings: $-114748000, EBIT: -12427000, Total Liabilities: $3677000, Revenue: $274000
AryaFin Target Price - $1.96 - Current Price $1.26 - Analyst Target Price $12.00
Ticker | BPTH |
Index | - |
Curent Price | 1.26 |
Change | -15.44% |
Market Cap | 4.59M |
Average Volume | 3.02M |
Income | -10.51M |
Sales | 0.00M |
Book Value/Share | -0.19 |
Cash/Share | 0.15 |
Dividend Est | - |
Dividend TTM | - |
Dividend Ex-Date | - |
Employees | 10 |
Moving Avg 20days | 61.86% |
Moving Avg 50days | 40.42% |
Moving Avg 200days | -34.36% |
Shares Outstanding | 4.31M |
Earnings Date | Nov 15 BMO |
Inst. Ownership | 1.37% |
Price/Earnings | - |
Forwad P/E | - |
PE Growth | - |
Price/Sales | - |
Price/Book | - |
Price/Cash | 8.20 |
Price/FCF | - |
Quick Ratio | 0.86 |
Current Ratio | 0.86 |
Debt/Equity | - |
Return on Assets | -263.29% |
Return on Equity | -1159.74% |
Return on Investment | - |
Gross Margin | - |
Ops Margin | - |
Profit Margin | - |
RSI | 66.52 |
BETA(β) | 0.09 |
From 52week Low | 112.38% |
From 52week High | -89.50% |
EPS | -12.20 |
EPS next Year | -1.55 |
EPS next Qtr | -0.37 |
EPS this Year | 90.57% |
EPS next 5 Year | - |
EPS past 5 Year | 34.89% |
Sales past 5 Year | 0.00% |
EPS Y/Y | 70.49% |
Sales Y/Y | - |
EPS Q/Q | 88.99% |
Sales Q/Q | - |
Sales Surprise | - |
EPS Surprise | 31.37% |
ATR(14) | 0.29 |
Perf Week | 90.56% |
Perf Month | 59.96% |
Perf Quarter | 44.83% |
Perf Year | -85.07% |
Perf YTD | -86.39% |
Target Price | 12.00 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer